Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7): SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7)

Inge van der Werf; Anna Wojtuszkiewicz; Huilan Yao; Rocco Sciarrillo; Manja Meggendorfer; Stephan Hutter; Wencke Walter; Jeroen Janssen; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach; Gerrit Jansen; Gertjan J. L. Kaspers; Richard Groen; Gert Ossenkoppele; Jacqueline Cloos

doi:https://doi.org/10.1038/s41375-021-01340-z

Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7): SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7)

Inge van der Werf, Anna Wojtuszkiewicz, Huilan Yao, Rocco Sciarrillo, Manja Meggendorfer, Stephan Hutter, Wencke Walter, Jeroen Janssen, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, Gerrit Jansen, Gertjan J. L. Kaspers, Richard Groen, Gert Ossenkoppele, Jacqueline Cloos

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Abstract

Despite carefully proofreading our submission, we missed a mistake in the affiliation of Wolfgang Kern, Claudia Haferlach and Torsten Haferlach. Instead of (2) H3 Biomedicine, their affiliation should be (3) MLL Munich Leukemia Laboratory, Munich, Germany.

Original language	English
Pages (from-to)	2735
Number of pages	1
Journal	Leukemia
Volume	35
Issue number	9
Early online date	2021
DOIs	https://doi.org/10.1038/s41375-021-01340-z
Publication status	Published - Sept 2021

Access to Document

https://doi.org/10.1038/s41375-021-01340-z

Cite this

van der Werf, I., Wojtuszkiewicz, A., Yao, H., Sciarrillo, R., Meggendorfer, M., Hutter, S., Walter, W., Janssen, J., Kern, W., Haferlach, C., Haferlach, T., Jansen, G., Kaspers, G. J. L., Groen, R., Ossenkoppele, G., & Cloos, J. (2021). Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7): SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7). Leukemia, 35(9), 2735. https://doi.org/10.1038/s41375-021-01340-z

van der Werf, Inge ; Wojtuszkiewicz, Anna ; Yao, Huilan et al. / Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7) : SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7). In: Leukemia. 2021 ; Vol. 35, No. 9. pp. 2735.

@article{90bd36463c2943ceb6d675f2bbc95567,

title = "Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7): SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7)",

abstract = "Despite carefully proofreading our submission, we missed a mistake in the affiliation of Wolfgang Kern, Claudia Haferlach and Torsten Haferlach. Instead of (2) H3 Biomedicine, their affiliation should be (3) MLL Munich Leukemia Laboratory, Munich, Germany.",

author = "{van der Werf}, Inge and Anna Wojtuszkiewicz and Huilan Yao and Rocco Sciarrillo and Manja Meggendorfer and Stephan Hutter and Wencke Walter and Jeroen Janssen and Wolfgang Kern and Claudia Haferlach and Torsten Haferlach and Gerrit Jansen and Kaspers, {Gertjan J. L.} and Richard Groen and Gert Ossenkoppele and Jacqueline Cloos",

year = "2021",

month = sep,

doi = "https://doi.org/10.1038/s41375-021-01340-z",

language = "English",

volume = "35",

pages = "2735",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "9",

}

van der Werf, I, Wojtuszkiewicz, A, Yao, H, Sciarrillo, R, Meggendorfer, M, Hutter, S, Walter, W, Janssen, J, Kern, W, Haferlach, C, Haferlach, T, Jansen, G , Kaspers, GJL , Groen, R , Ossenkoppele, G & Cloos, J 2021, 'Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7): SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7)', Leukemia, vol. 35, no. 9, pp. 2735. https://doi.org/10.1038/s41375-021-01340-z

Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7): SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7). / van der Werf, Inge; Wojtuszkiewicz, Anna; Yao, Huilan et al.
In: Leukemia, Vol. 35, No. 9, 09.2021, p. 2735.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7)

T2 - SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7)

AU - van der Werf, Inge

AU - Wojtuszkiewicz, Anna

AU - Yao, Huilan

AU - Sciarrillo, Rocco

AU - Meggendorfer, Manja

AU - Hutter, Stephan

AU - Walter, Wencke

AU - Janssen, Jeroen

AU - Kern, Wolfgang

AU - Haferlach, Claudia

AU - Haferlach, Torsten

AU - Jansen, Gerrit

AU - Kaspers, Gertjan J. L.

AU - Groen, Richard

AU - Ossenkoppele, Gert

AU - Cloos, Jacqueline

PY - 2021/9

Y1 - 2021/9

N2 - Despite carefully proofreading our submission, we missed a mistake in the affiliation of Wolfgang Kern, Claudia Haferlach and Torsten Haferlach. Instead of (2) H3 Biomedicine, their affiliation should be (3) MLL Munich Leukemia Laboratory, Munich, Germany.

AB - Despite carefully proofreading our submission, we missed a mistake in the affiliation of Wolfgang Kern, Claudia Haferlach and Torsten Haferlach. Instead of (2) H3 Biomedicine, their affiliation should be (3) MLL Munich Leukemia Laboratory, Munich, Germany.

UR - http://www.scopus.com/inward/record.url?scp=85109800171&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41375-021-01340-z

DO - https://doi.org/10.1038/s41375-021-01340-z

M3 - Comment/Letter to the editor

C2 - 34272482

SN - 0887-6924

VL - 35

SP - 2735

JO - Leukemia

JF - Leukemia

IS - 9

ER -

van der Werf I, Wojtuszkiewicz A, Yao H, Sciarrillo R, Meggendorfer M, Hutter S et al. Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7): SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7). Leukemia. 2021 Sept;35(9):2735. Epub 2021. doi: https://doi.org/10.1038/s41375-021-01340-z

Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (10.1038/s41375- 021-01273-7): SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (Leukemia, (2021), 35, 9, (2698-2702), 10.1038/s41375-021-01273-7)

Abstract

Access to Document

Other files and links

Cite this